The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1758-9193
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients ; volume:13 ; number:1 ; day:25 ; month:9 ; year:2021 ; pages:1-10 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (25.9.2021), 1-10, 12.2021

Creator
Targa, Adriano D. S.
Benítez, Iván D.
Dakterzada, Faridé
Fontenele-Araujo, John
Minguez, Olga
Zetterberg, Henrik
Blennow, Kaj
Barbé, Ferran
Piñol-Ripoll, Gerard
Contributor
SpringerLink (Online service)

DOI
10.1186/s13195-021-00903-7
URN
urn:nbn:de:101:1-2021121619435817985889
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Targa, Adriano D. S.
  • Benítez, Iván D.
  • Dakterzada, Faridé
  • Fontenele-Araujo, John
  • Minguez, Olga
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Barbé, Ferran
  • Piñol-Ripoll, Gerard
  • SpringerLink (Online service)

Other Objects (12)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease

BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease

Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study

Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Related objects